The Capio PCC model demonstrated a notable 43% reduction in MRI indications compared with PSA ≥ 3 ng/ml when using Stockholm3 ≥ 15, showcasing its efficacy in optimizing prostate cancer diagnostics. Here, KLK3 is linked to prostate carcinoma.